Larimar Therapeutics, Inc. quarterly report, Q1 FY2016

Business Context and Reporting Period

Entity discrepancy: The supplied filing is Zafgen, Inc.’s Form 10-Q for the quarter ended March 31, 2016, not a filing by Larimar Therapeutics, Inc. This summary describes the filing text provided. Financial statements are unaudited.

Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for obesity and metabolic disorders. Its lead candidate, beloranib, was under full FDA clinical hold; ZGN-839 and second-generation candidates remained at earlier development stages. The company had no product revenue.

Financial Results and Liquidity

Operating expenses increased $4.6 million year over year. R&D growth largely reflected personnel, consulting and stock-based compensation; G&A growth reflected stock-based compensation and professional fees. Gross margin is not meaningful because the company reported no revenue.

At March 31, 2016, cash and cash equivalents were $31.5 million and marketable securities were $134.7 million, totaling approximately $166.2 million. Current assets were $168.8 million; current liabilities were $12.9 million. Total liabilities were $15.6 million, including notes payable of $5.4 million principal. The debt carried an approximately 10.8% effective annual interest rate and was secured by substantially all personal property other than intellectual property. Stockholders’ equity was $154.4 million and accumulated deficit was $197.4 million.

Cash and cash equivalents declined $4.1 million during the quarter. Investing activities provided $14.3 million, primarily from net marketable-security maturities; financing activities used $0.7 million, mainly for debt repayments. The company reported no off-balance-sheet arrangements.

Material Changes Versus the Prior Comparable Period

• Net loss widened by $4.3 million, while operating cash use increased by $6.7 million.
• R&D expense rose $2.3 million and G&A expense rose $2.3 million. Beloranib clinical-trial spending increased modestly; ZGN-839 spending fell after the company withdrew its IND in January 2016 to gather additional data on potential thrombosis risk.
• Unlike Q1 2015, which included $129.6 million in net financing cash inflows from a follow-on offering, Q1 2016 had no public-offering proceeds.
• Cash, cash equivalents and marketable securities declined from $175.4 million at December 31, 2015 to $166.2 million at March 31, 2016.

Outlook, Risks, Contingencies and Unusual Items

• Management estimated that available cash, cash equivalents and marketable securities would fund operating expenses and capital expenditures for approximately 18 months from March 31, 2016. The estimate depended on assumptions that could prove incorrect; the company expected to need additional financing over time.
• The FDA imposed a full clinical hold on beloranib in December 2015 after thrombotic events in treated patients, including two deaths from pulmonary embolism. The company planned to submit completed trial data and a proposed PWS risk-mitigation strategy to seek resolution; resumption of development and timing of any FDA decision were uncertain.
• The company reported top-line results from its completed Phase 3 PWS trial: co-primary efficacy endpoints for body weight and hyperphagia-related behaviors were met. The filing cautioned that results might not be replicated and stated that further trials would likely be needed even if the hold were lifted.
• Management expected continued significant expenses and operating losses. Development, regulatory approval and commercialization were uncertain, and the company might need equity, debt or collaboration financing, potentially diluting shareholders or requiring concessions of rights.
• A putative securities class action alleged misleading statements concerning beloranib trials and sought unspecified damages. The company filed a motion to dismiss on April 7, 2016; it said it could not estimate possible losses.
• Beloranib license agreements included up to $12.3 million in pre-commercialization milestones, up to $12.5 million in commercialization milestones, and potential royalties. No milestones were achieved in the quarter. Operating leases had $0.8 million in disclosed future minimum payments.
• Market risks included interest-rate sensitivity (a hypothetical $0.3 million fair-value decline from an immediate 50-basis-point increase) and unhedged currency exposure (an estimated $0.1 million increase in quarterly net loss from a 10% unfavorable exchange-rate movement).

Most Important Facts for Investors to Verify

• Confirm the issuer and reporting period: the provided document names Zafgen, Inc., despite the Larimar Therapeutics metadata.
• Check subsequent FDA decisions on the beloranib clinical hold, safety findings and any required risk-mitigation measures or additional studies.
• Review full clinical-trial safety and efficacy data, including thrombotic events and whether efficacy findings are reproducible.
• Assess cash burn, financing needs and whether the stated approximately 18-month runway assumptions remained valid.
• Track the securities lawsuit, potential exposure under beloranib licenses, and debt repayment obligations.